Scientists make pain-control discovery
Breakthrough could lead to drugs to help fight depression and addiction as well as discomfort
Steve Connor is the Science Editor of The Independent. He has won many awards for his journalism, including five-times winner of the prestigious British science writers’ award; the David Perlman Award of the American Geophysical Union; twice commended as specialist journalist of the year in the UK Press Awards; UK health journalist of the year and a special merit award of the European School of Oncology for his investigative journalism. He has a degree in zoology from the University of Oxford and has a special interest in genetics and medical science, human evolution and origins, climate change and the environment.
Thursday 22 March 2012
New drugs for treating a range of illnesses from depression to chronic pain could result from studies that reveal for the first time the detailed molecular structure of the brain's "pleasure molecules", scientists said.
Researchers have deciphered the atomic three-dimensional structure of the brain's opioid receptors, the protein molecules that are intimately involved in the control of pain and feelings of wellbeing, as well as being the target of the opioid drugs such as morphine, codeine and heroin.
They said that unravelling of the structure of the opioid receptors on such a minutely detailed level will accelerate the development of new drugs that can alleviate anxiety and depression as well as novel treatments for chronic pain and addiction.
"Once we see the structure of the receptor, it becomes easier for us to develop drugs that target the receptor in ways that might be beneficial for medical therapy," said Professor Bryan Roth of the University of North Carolina School of Medicine in Chapel Hill.
There are four types of opioid receptor which work together in ways that are not completely understood. Two of them have been deciphered by two teams of researchers who published their work in the journal Nature.
Professor Roth's group worked on the "kappa" opioid receptor which is known to respond to one of the most powerful natural hallucinogenic drugs, salvinorin A, which is derived from the plant Salvia divinorum, commonly known as "magic mint".
According to the US National Institute on Drug Abuse there has been a surge in the use of salvia among young Americans, with more than one in 20 young adults saying they have experimented with magic mint in the past year.
The second opioid receptor analysed in detail is the "mu" opioid which is involved in the control of pleasure and pain-relief by binding to the body's endorphin neurotransmitters. The same receptor is targeted by synthetic opioid drugs such as morphine, codeine and heroin – as well as opium.
While the kappa opioid receptor appears to elevate a person's mood, the mu receptor can depress mood and produce "dissociative psychedelic experiences", which is how magic mint produces its effect, the scientists said.
Studies on laboratory animals have indicated the drugs that can block the action of the kappa opioid receptors could be used to treat addiction, provide pain-relief and reduce the symptoms of irritable bowel syndrome, he said.
Even the psychedelic effect associated with the activation of the kappa receptor protein could be useful in providing fresh insights into human perception and consciousness, Professor Roth said.
Update: Spelling of opioid corrected.
The magicians using online collaboration to push boundaries
Jennifer Lawrence attacks mass media again over body image
Jennifer Lawrence: 'It should be illegal to call someone fat on TV'
Colin Farrell reveals ‘affair’ with Elizabeth Taylor: 'She was my last romantic relationship'
Ian Watkins: Paedophile Lostprophets singer sentenced to 35 years for child sex offences, as judge labels him a 'dangerous sexual predator'
Children evacuated from swimming pool after prosthetic leg mistaken for paedophile
Devyani Khobragade: India-US row escalates over arrest of diplomat in New York
Exclusive: Young people ‘want UK to stay in Europe’: Four in 10 adults aged 18 to 24 are ‘firmly in favour’ of membership, poll shows
You can STILL be jailed for being a republican, government confirms, and it remains illegal to even 'imagine' overthrowing the Queen
Kiss and yell: Italian protester charged with sexual assault after kissing riot police officer
Fighting back: the woman giving a voice (and 49,999 others) to the victims of sexism - by giving an airing to their horror stories
PM denies two child limit for benefits is part of Tory welfare policy
Ethan Couch: Texas quadruple murderer – or a victim of ‘affluenza’?
- 1 America's 'virgin births'? One in 200 mothers 'became pregnant without having sex'
- 2 Sun will 'flip upside down' within weeks, says Nasa
- 4 Christmas comes early: Justin Bieber announces he's 'retiring from music'
- 5 Children evacuated from swimming pool after prosthetic leg mistaken for paedophile
- < Previous
- Next >
£25000 - £32000 per annum: Harrington Starr: Junior Business Analyst - Banking...
£21999 - £27001 per annum + Benefits: Pro-Recruitment Group: Do you have exten...
£25000 - £35000 per annum + benefits + bonus: Harrington Starr: Business Analy...
£42000 - £51000 per annum + Benefits: Pro-Recruitment Group: Are You Receiving...